Actylis Appoints Scott Thomson as CEO
Actylis, a global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets formed in 2022, appointed Scott Thomson as new Chief Executive Officer.
Scott Thomson, who succeeds Gilles Cottier at the helm of the Port Washington, NY-based CDMO, has a three-decade track record in the pharmaceutical and chemical industries, where he has helped companies drive long-term growth and lead the sustainable improvement of strategic business development and execution. Most recently, as of October 2020, Scott was the CEO of SPI Pharma. Prior to that role, he was a senior executive at BASF, where he was responsible for several global life science and specialty ingredients businesses. In total, he spent 29 years at BASF in senior roles, including Senior Vice President for North America Care Chemicals and Global Pharmaceutical Solutions.
Joe Walker, Managing Director at New Mountain Capital, said, “Since New Mountain’s investment in 2019, Actylis has transformed into a leading manufacturer and distributor of key ingredients in pharma, biopharma, nutritional, agri-science, cosmetics and specialty chemicals markets, completing seven acquisitions and substantially expanding the company’s global reach."
Actylis offers standard and custom ingredients through a rapidly growing portfolio of GMP and non-GMP facilities worldwide, as well as through the company’s strong sourcing partner network. Actylis’ hybrid manufacturing and global sourcing model for ingredients and raw materials delivers the most flexible and reliable solutions for its customers’ unique manufacturing requirements, supported by industry-leading standards of quality documentation and regulatory compliance.
Scott Thomson, newly elected CEO of Actylis, commented: “I feel privileged to lead the Actylis team at this exciting juncture, and I look forward to partnering with our customers, Actylis’ management and employees, and New Mountain to grow and further develop Actylis’ offerings. There is significant opportunity to accelerate the company’s growth and I look forward to building upon the company’s achievements to date both organically and inorganically.”
